Hemodynamics, fluids & transfusion
Overview of the current use of levosimendan in France: a prospective observational cohort study
An erratum to this article was published (Ann Intensive Care, 29 Sep 2023 ↗)
Authors' conclusion
We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent.
Study context
- Population
- Patients treated with levosimendan in France (France-LEVO registry)29.6% of national yearly use
- Participants
- 602 patients
- Exposure
- Cardiogenic shock vs Decompensated heart failure vs Cardiac surgery vs Weaning from veno-arterial extracorporeal membrane oxygenation
- Cardiogenic shockn = 250
- Decompensated heart failuren = 127
- Cardiac surgeryn = 86
- Weaning from veno-arterial extracorporeal membrane oxygenationn = 82
- Outcome
- Indications and dosing of levosimendan
Methodological detailsnational registry
- National registry
Main finding
As reported in the abstract
- Infusion rate (mean ± SD 0.07)
- 0.18 µg/kg/min
- Infusion duration (mean ± SD 8)
- 26 h
- Initial bolus
- 45 (7.5%)
- Repeated infusions
- 103 (17.1%)
- Concomitant inotropes and/or vasoactive agents
- 461 (76.6%)
Observational data: associations, not effects.
Further findings
Mortality
- In-hospital death
- 136 (22.6%)
- Death during 90-day follow-up
- 26 (4.3%)
Safety
- Hypotension
- 218 (36.2%)
- AF
- 85 (14.1%)
- Serious adverse events
- 17 (2.8%)
Original publication
Overview of the current use of levosimendan in France: a prospective observational cohort study. Ann Intensive Care. Published 8 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →